Patents Assigned to Merck
  • Calibration device for an optical detector and setting device for setting calibration points for the calibration device
    Patent number: 11785683
    Abstract: The present invention provides a calibration device for an optical detector comprising a light emitting diode 1, and an electronic circuit 3 for driving the light emitting diode 1, wherein the electronic circuit 3 is a constant current generator configured to supply a constant driving current to the light emitting diode 1 in the range of 0.5 to 25 ?A. Furthermore, the present invention provides a setting device for setting at least one calibration point for a calibration device as described above. The setting device comprises a light detector 51 configured to output a signal representing the light emission intensity of a calibration device under examination, a controller 53 for controlling the constant driving current of the calibration device under examination, and a calibration point setting means 55 for setting at least one calibration point for the calibration device under examination.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: October 10, 2023
    Assignee: MERCK PATENT GmbH
    Inventors: Fabrice Comini, Frederick G. Bargoot, Victor Etre
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20230312694
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: December 23, 2022
    Publication date: October 5, 2023
    Applicants: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • SYSTEM FOR TREATING A BIOTECHNOLOGICAL FLUID
    Publication number: 20230313114
    Abstract: The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network.
    Type: Application
    Filed: August 19, 2021
    Publication date: October 5, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Rene REINBIGLER, Denis DUBRET, Steve MILLER
  • 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20230312528
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 5, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
  • PROCESS FOR PREPARING SUGAMMADEX
    Publication number: 20230312887
    Abstract: The present invention relates to a process for drying crystalline sugammadex to meet solvent specifications that is independent of API crystallinity or crystalline form generated. It further relates to use of sugammadex in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 5, 2023
    Applicants: Merck Sharp & Dohme LLC, Werthenstein BioPharma GMBH
    Inventors: David J. Lamberto, Paolo Avalle, Lorenzo Codan, Patrick Larpent, Jochen Schoell, Jeffrey S. Neuhaus
  • INJECTABLE DEPOT COMPOSITIONS FOR THE DELIVERY OF ANTIVIRAL AGENTS
    Publication number: 20230310309
    Abstract: This invention relates to novel injectable depot compositions for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: August 23, 2021
    Publication date: October 5, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephanie Elizabeth Barrett, Seth P. Forster, Marian E. Gindy
  • DEVICE AND PROCESS FOR CELL CULTURE MEDIA PREPARATION AND PERFORMING CELL CULTURE
    Publication number: 20230313109
    Abstract: The present invention relates to a device and processes for producing liquid media for cell cultures, whereby the liquid media are produced automatically by dissolving ingredients in water. The present invention also relates to a device for producing media used in cell cultures or a substance produced by cell cultures using a bioreactor process.
    Type: Application
    Filed: July 5, 2021
    Publication date: October 5, 2023
    Applicant: Merck Patent GmbH
    Inventors: Jochen Bastian SIECK, Christian SCHULTHEISS
  • DEVICE
    Publication number: 20230320140
    Abstract: The present invention relates to a color conversion device (100).
    Type: Application
    Filed: September 1, 2021
    Publication date: October 5, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Tadashi KISHIMOTO, Atsuko NOYA, Julian BURSCHKA, Teruaki SUZUKI, Daishi YOKOYAMA, Seishi SHIBAYAMA
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20230310551
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 5, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Christina B. Madsen-Duggan, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
  • METAL COMPLEXES
    Publication number: 20230320191
    Abstract: The present invention relates to iridium complexes suitable for use in organic electroluminescent devices, especially as emitters.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 5, 2023
    Applicant: Merck Patent GmbH
    Inventors: Philipp Stoessel, Armin Auch
  • OPTICAL COMPONENT
    Publication number: 20230313043
    Abstract: The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III in which the occurring groups and parameters have the meanings defined in claim 1, and preferably one or more compounds of the formula RO in which the occurring groups and parameters have the meanings defined in claim 2.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 5, 2023
    Applicant: Merck Patent GmbH
    Inventors: Izumi SAITO, Owain Llyr PARRI, Andreas TAUGERBECK, Carsten FRITZSCH, Dagmar KLASS
  • Progressively-trained scale-invariant and boundary-aware deep neural network for the automatic 3D segmentation of lung lesions
    Patent number: 11776130
    Abstract: A system and method are disclosed for segmenting a set of two-dimensional CT slices corresponding to a lesion. In an embodiment, for each of at least a subset of the set of CT slices, the system inputs the CT slice into a plurality of branches of a trained segmentation block. Each branch of the segmentation block includes a convolutional neural network (CNN) with filters at a different scale, and produces a plurality of levels of output. The system generates, for each CT slice in the subset, feature maps for each level of output. The system generates a segmentation of each CT slice in the subset based on the feature maps of each level of output. The system aggregates the segmentations of each slice in the subset to generate a three-dimensional segmentation of the lesion. The system provides data representing the three-dimensional segmentation for display.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: October 3, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Antong Chen, Gregory Goldmacher, Bo Zhou
  • Effect pigments
    Patent number: 11773270
    Abstract: The present invention relates to effect pigments which are based on flake-form substrates having a circular form factor of 1.2-2 and are coated with at least one high-refractive-index layer, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in cosmetic formulations.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: October 3, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Gerhard Pfaff, Stephanie Andes, Klaus Ambrosius, Ralf Petry, Michael Roesler, Sabine Schoen
  • Composition for organic electronic devices
    Patent number: 11778907
    Abstract: The present invention relates to a composition comprising a bipolar host and an electron-transporting host, especially for use as matrix material in electronic devices, especially organic electroluminescent devices, and especially in an organic light-emitting diode (OLED). The invention further relates to electronic devices comprising said composition.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Jonas Kroeber, Christian Eickhoff, Tobias Grossmann, Aurélie Ludemann, Dominik Joosten
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
    Patent number: 11773150
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: October 3, 2023
    Assignees: Merck Sharp & Dohme LLC, Ambrx, Inc.
    Inventors: Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20230303540
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: September 1, 2021
    Publication date: September 28, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John J. Acton, III, Ryan Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon Kattar, Mitchell H. Keylor, Derun Li, Kaila A. Margrey, Gregori J. Morriello, Xin Yan
  • COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
    Publication number: 20230301991
    Abstract: The present invention encompasses ATR inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: October 22, 2021
    Publication date: September 28, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Ulrich BETZ, Thomas FUCHSS
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20230301981
    Abstract: Compounds disclosed herein and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 28, 2023
    Applicant: Merck Patent GmbH
    Inventors: Lukas Shinji Okitsu, Julie DeMartino, Thomas Spangenberg
  • Process for making beta 3 agonists and intermediates
    Patent number: 11767292
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: September 26, 2023
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong